Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained a price target of $10.
August 10, 2023 | 8:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Verrica Pharmaceuticals and maintained a price target of $10.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $10 price target indicates a positive outlook for Verrica Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100